Irene Uceda posted this:
Employee at Consejo Superior de Investigaciones Científicas
Consejo Superior de Investigaciones Científicas posted this:Molecular Method that radically improves the diagnosis of Hereditary hemorrhagic telangiectasia (HHT)Molecular Method that radically improves the diagnosis of Hereditary hemorrhagic telangiectasia (HHT). The Granada University, Health and Progress Foundation, and the CSIC have developed a diagnostic molecular system for the HHT by getting a simple liquid biopsy from the patient. Industrial partners are being sought to collaborate through a patent license agreement to use this molecular diagnostic system with the possibility of informatics support.
Universidad de Alcalá-OTRI posted this:Development and method of construction of a new electrochemical sensor of Magnesium (Mg2 +), without the need to add organic salts, additives or organic solvents to the sampleThe research group in Bioelectrochemistry and Biosensors of the University of Alcalá in collaboration with the Textile Industry Research Association (AITEX) has developed an electrochemical sensor of magnesium (Mg2 +) and a construction method based on the formation of a polymeric three-dimensional network that allows the entrapment / immobilization of a selective indicator for Mg2 +, eriochrome black T, by the use of a crosslinking agent and a polymer. The combination of these three reagents allows the construction of the sensor on any conductive surface, avoiding the electro polymerization of the indicator. The resulting sensor allows to measure MG2 + in any type of samples, without the need to add organic salts, additives or organic solvents. The quantification of Mg2 + is done directly by incubating the sensor in the sample containing the analyte, resulting in a modification of the amperometric signal proportional to its concentration. This method has many applications especially in health and biomedical sector since Mg2 + participates in such important activities as neuronal, neuromuscular transmission, or regulation of blood pressure and plays a key role in various pathologies such as vascular and migraines headache. The group is looking for companies in the agro-food, bio-sanitary and environmental sectors, with the aim of reaching technical collaboration agreements, commercial agreements or patent licenses.
Germans Trias i Pujol Health Sciences Research Institute posted this:Apotransferrin to treat strokeOur group has demonstrated that intravenous administration of apotransferrin strongly reduces the brain damage (up to 75%) in 3 different rat models including both transient and permanent ischemic stroke and improves the neurological impairment (neuroscore 60%) induced by stroke. Thus, this new approach may benefit not only stroke patients who can be treated with current treatment to induce recanalization (transient stroke) but also the 80% of patients who could not benefit from current therapies directed to induce recanalization of the artery (permanent strokes). Results in the preclinical area and some results obtained in serum of stroke patients lead us to think that apotransferrin is a good neuroprotector in the early stages of the ischemic event.
Universidad de Alcalá-OTRI posted this:Procedure for obtaining peptides with antioxidant and antihypertensive properties from olive seeds.A research group from the Analytical Chemistry Department at Alcalá University has developed a procedure from which it is possible to obtain peptides with antihypertensive and antioxidant capacity of isolated proteins from olive seed by enzymatic digestion. The method consists of the protein extraction from the olive seeds using a previously developed process, and digest the extracted proteins with Thermolysin enzyme, allowing to obtain peptides with antihypertensive capacity in vitro, or with Alcalase enzyme leading to obtain a peptide extract with antioxidant properties. The group seeks to establish commercial , licensing or collaboration agreements with companies of the food and pharmaceutical sectors interested in both the use strategy of this waste material (olive pits), as in the use of the found bioactive peptides.
Universidad de Alcalá-OTRI posted this:Device and method for ventricular repolarization alternans detection by windowing.A Spanish research group from the Department of Signal Theory and Communications at University of Alcalá (Spain) has designed a device and method for detecting ventricular repolarization alternans based on continuous time analysis and the extraction of the information using windowing. As a main feature, the method presents high robustness against noise and it is very robust against variability of heart rate due to standardization techniques used. Moreover, it includes a procedure to separate the repolarization information from artifacts. Because of these characteristics, it is particularly suitable for implementation in portable monitoring devices and implantable devices. The group is looking for companies of Medical equipment and health technology to reach licensing agreements or collaboration and commercial agreements for technical assistance.
Germans Trias i Pujol Health Sciences Research Institute posted this:Innovative device for electro-mechanical stimulation for tissue engineering applicationsThe device presented enables the combination of both electrical and mechanical stimulation either independently or simultaneously. The mechanical stimulation is performed with a non-invasive and aseptic novel approach. A sterile, single use device is placed into a standard culture plate. The cells are seeded in a volume contained in the central area of the device, which goes through mechanical stimulation thanks to the embedded magnets and the external magnetic field.
Centre Technology Transfer CITTRU posted this:The method for evaluation of endothelial function based on the measurement of changes in skin fluorescence induced by blood flow perturbationFlow Mediated Skin Fluorescence (FMSF) method meets the demand for a simple, fast, inexpensive, non-invasive test for the assessment of endothelial function that is reliable, easy to carry, and thus it is possible to apply for a large population of patients, e.g. for the purpose of screening and monitoring the patient's response to treatment. It allows the assessment of both systole (LFR) and diastole of blood vessels (HFR), and also allows to track the kinetics of changes in response to reactive hyperemia. FMSF method allows the detection of vascular endothelial dysfunction at an early stage of the disorder to identify patients for preventive or therapeutic intervention, or to more accurate and more complex diagnostic tests. FMSF method allows to monitor the healing process, to observe the influence of drugs on the vascular condition, or the influence of exercise training on overall health. FMSF method has already acquired intellectual property protection in the EU (decision of the intention to grant a patent - European patent application EP12727444.7); the patent procedure in other largest markets worldwide is ongoing. Further details are enclosed in attached documents.
Technology Transfer Office
RAMOT at Tel Aviv University Ltd. posted this:Iron oxide nanoparticles (IOP) for the treatment of acute myocardial infarction (AMI) and other inflammatory conditionsA novel approach for the treatment of AMI has been developed using IOPs. IOPs, when injected into the infarcted myocardium, lead to improved heart function after MI. IOPs activate anti-inflammatory macrophages and thus promote tissue healing and repair and prevent myocardial remodeling and dysfunction. Potential Applications IOPs can be used to treat AMI and other inflammatory conditions associated with pro-inflammatory activated macrophages and to promote tissue healing and repair. Advantages ? IOPs are nontoxic ? IOPs are FDA approved for use in humans for MRI imaging Stage In vivo studies in mouse and rat models of MI and heart failure Project ID : 10-2011-247
IDIBELL posted this:Companion diagnostic for cutaneous and uveal melanomaCompanion diagnostic for cutaneous and uveal melanoma. Our combination drug therapy for metastatic melanoma offers an alternative treatment for patients that do not have the BRAF V600 mutation or for patients resistant to Vemurafenib. Additionally, our technology can be used as a prognostic test to predict the risk of metastasis in uveal and cutaneous melanoma.
UACOOPERA University of Aveiro posted this:
Technology Transfer Office at uacoopera